Pharmaceutical Technology

DECEMBER 4, 2022

Starting in January, multiple biosimilars of AbbVie’s blockbuster drug Humira are set to flood the US pharmaceutical market. The arrival of Humira biosimilars is expected to provide cost-effective alternatives to the anti-tumor necrosis factor (TNF) biologic, but their eventual position on the market remains to be seen.

Biosimilars 104

Biosimilars Labelling Communication Hospitals 104

Pharmaceutical Technology

DECEMBER 9, 2022

Instead, the focus remains on its domestic industry, particularly around biosimilars, while reducing reliance on imports and branded pharmaceuticals. While Brazil remains a high-growth market, investment in innovative pharmaceuticals is still limited. </p> By Tanner Pharma Group.

Drug Pricing 98

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 98

pharmaphorum

FEBRUARY 1, 2021

A push for biosimilars. 2021 will see simplified requirements for biosimilars being implemented. Companies can let AIFA know about biosimilars coming to market giving 30 days notice from the end of the originator patent. Lower paybacks possible. The Italian industry makes regular paybacks when spending ceilings are breached.

Biosimilars 52

Biosimilars Hospitals 52

FDA Law Blog: Biosimilars

APRIL 8, 2024

It also noted that last year, FDA hosted a two-day public workshop and published a white paper on the regulatory framework for Artificial Intelligence in drug manufacturing, in addition to other efforts. Like many of us, OPQ seems intent on trying to keep up with how technology can/will impact pharmaceutical quality.

Immunity 59

Immunity Immunization 59

Pharmaceutical Technology

JANUARY 16, 2023

However, low-cost generic and biosimilar manufacturers are likely to be particularly exposed to these economic pressures. By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Pharmaceutical Technology

JANUARY 16, 2023

However, low-cost generic and biosimilar manufacturers are likely to be particularly exposed to these economic pressures. By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

FDA Law Blog: Biosimilars

APRIL 8, 2024

Department of Health and Human Services (HHS) recently published a White Paper on Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States —with input from several HHS stakeholders, including FDA, CMS, and the Administration for Strategic Preparedness and Response. By Kalie E.

Inpatient 59

Inpatient Hospitals Dosage Controlled Substances 59